


[FIG. 1]


NAFLD activity score (NAS)
5
4
3
2
1
0
***
***
***
Normal mice, Excipient
NASH-induced mice, Excipient
NASH-induced mice, Long-acting conjugate of SEQ ID NO: 42 0.36 nmol/kg, Q2D
NASH-induced mice, Long-acting conjugate of SEQ ID NO: 42 0.72 nmol/kg, Q2D
NASH-induced mice, Long-acting conjugate of SEQ ID NO: 42 1.44 nmol/kg, Q2D


[FIG. 2]


Triglyceride
Cholesterol
Hepatic TG (mg/g liver)
Hepatic cholesterol (mg/g liver)
200
150
100
50
0
40
30
20
10
0
***
†††
Normal, Excipient control group
AMLN, Excipient control group
AMLN, Obeticholic Acid 30 mg/kg, QD
AMLN, Long-acting conjugate of SEQ ID NO: 42 2.6 nmol/kg, Q2D

[FIG. 3]


Steatosis score
3
2
1
0
***
†††
***
Norrmal, Excipient control group
AMLN, Excipient control group
AMLN, Obeticholic Acid 30 mg/kg, QD
AMLN, Long-acting conjugate of SEQ ID NO: 42
2.6 nmol/kg, Q2D
Normal, Excipient
AMLN, Excipient
AMLN, Obeticholic Acid
AMLN, Long-acting conjugate of SEQ ID NO: 42
[scale bar. 100 μm]

[FIG. 4]




ELF Score: $2.278 + 0.851 \ln(C_{HA}) + 0.751 \ln(C_{PIIINP}) + 0.394 \ln(C_{TIMP1})$

AMLN, Excipient control group


AMLN/TAA, Excipient control group

AMLN/TAA, Long-acting conjugate of SEQ ID NO: 42 1.3 nmol/kg, Q2D


[FIG. 5]


5
4
3
2
1
0
% of positive area
**
*
AMLN, Excipient control group
AMLN/TAA, Excipient control group
AMLN/TAA, Long-acting conjugate of SEQ ID NO: 42 1.3 nmol/kg, Q2D


[FIG. 6]


TIMP-1
TIMP-1 (ng/mL)
80
60
40
20
0
***
†††
***
Hyaluronic acid
Hyaluronic acid (ng/mL)
1600
1200
800
400
***
†††
***
Sham, Excipient control group
BDL, Excipient control group
BDL, obeticholic acid 30 mg/kg, QD
BDL, Long-acting conjugate of SEQ ID NO: 42 1.3 nmol/kg, Q2D


[FIG. 7a]


Sham, Excipient control group
BDL, Excipient control group
BDL, Long-acting conjugate of SEQ ID NO: 42


[FIG. 7b]


2.0
1.5
1.0
0.5
fibrosis scroe
***
**
Sham, Excipient control group
BDL, Excipient control group
BDL, Long-acting conjugate of SEQ ID NO: 42 1.3 nmol/kg, Q2D


[FIG. 8]


Sham, Excipient control group
BDL, Excipient control group
BDL, obeticholic acid
BDL, Long-acting conjugate of triple agonist
Inflammation score
2.0
1.5
1.0
0.5
***
*
*
Sham, Excipient control group
BDL, Excipient control group
BDL, obeticholic acid 30 mg/kg, QD
BDL, Long-acting conjugate of SEQ ID NO: 42 1.3 nmol/kg, Q2D


[FIG. 9]


Sham, Excipient control group
BDL, Excipient control group
BDL, Long-acting conjugate of triple agonist
Parenchymal necrosis score
3.0
2.5
2.0
1.5
1.0
0.5
***
*
Sham, Excipient control group
BDL, Excipient control group
BDL, Long-acting conjugate of SEQ ID NO: 42 1.3 nmol/kg, Q2D


[FIG. 10]


2.0
1.5
1.0
0.5
Bile duct hyperplasia
***
*
Sham, Excipient control group
BDL, Excipient control group
BDL, Long-acting conjugate of SEQ ID NO: 42
1.3 nmol/kg, Q2D

[FIG. 11]


MCP-1
IL-6
Relative expression (Fold increase)
2.0
1.5
1.0
0.5
0.0
AMLN, Excipient control group
AMLN/TAA, Excipient control group
AMLN/TAA, Long-acting conjugate of SEQ ID NO: 42 1.3 nmol/kg, Q2D

[FIG. 12]


Human macrophage cell line (THP-1 cell line)
Human tumor necrosis
250
200
150
100
50
0
***
***
Negative control w/PMA 150 nM
Positive control PMA+LPS 100 ng/mL
PMA+Triple agonist of SEQ ID NO: 42 1μM+LPS
PMA+Triple agonist of SEQ ID NO: 66 1μM+LPS
PMA+Triple agonist of SEQ ID NO: 67 1μM+LPS
PMA+Triple agonist of SEQ ID NO: 97 1μM+LPS
PMA+Triple agonist of SEQ ID NO: 100 1μM+LPS